Skip to main content
Featured Article
The magnitude of benefit of immune checkpoint inhibitors on overall survival for patients with advanced cancers is sex-dependent.
Compared to testing for BRCA1/2 mutations only, testing for multiple breast cancer-associated genes improves detection of pathogenic variants.
The FDA released information about decreased survival rates associated with the use of two different drugs.
A 60-year-old woman presented with a persistent dry cough, extreme fatigue, and a decrease in appetite following a diagnosis of streptococcal…
Treating early stage breast cancer patients for just six months with trastuzumab works as well as the current 12-month regimen.
Ayalew Tefferi, MD, talks about the revised MIPSS version 2.0 and what it means for the future of primary myelofibrosis.
Three-month post-radiotherapy prostate specific antigen levels may be a strong prognostic biomarker for treatment response in patients with…
Special Report
This report will help oncology care providers understand the significance of ALK gene rearrangements for NSCLC as well as the potential benefits of…
Live Events

Live Events